ABOUT THE COVER
The cover features a molecular modeling diagram depicting molecular interaction between LY294002, the active moiety of SF1126, and the BRD4 bromodomain binding domain 1 (BD1). SF1126 is the first known dual inhibitor of PI3K and BRD4 in a single chemotype. The figure shows LY294002 and JQ1 docked at the key acetyl-lysine recognition pocket of BRD4-BD1. LY294002 is displayed with brown carbons and JQ1 with magenta carbons. SF1126 will enter clinical trials in liver cancer this year. For details, see the article by Singh, Joshi, and Burgoyne et al on page 2553.